Global Antiphospholipid Syndrome (APS) Market - 2024-2031

Global Antiphospholipid Syndrome (APS) Market - 2024-2031

The global antiphospholipid syndrome market reached US$ 32.87 billion in 2023 and is expected to reach US$ 68.43 billion by 2031 growing with a CAGR of 9.6% during the forecast period 2024-2031.

Antiphospholipid Syndrome is characterized by an increased tendency to form abnormal blood clots that block the blood vessels. The blood clot can develop in any blood vessel in the body such as in the legs, lungs, and other organs, such as the kidneys and spleen. In antiphospholipid syndrome, the immune system produces abnormal antibodies called antiphospholipid antibodies that target the proteins attached to fat molecules which makes the blood more likely to clot.

The market is driven by factors such as the increasing clinical trials of treatment drugs, the prevalence of antiphospholipid syndrome, and rising research and developments.

Market Dynamics: Drivers

Increasing Clinical Trials for Antiphospholipid Syndrome

The global antiphospholipid syndrome market has witnessed significant growth due to various recent clinical trials. Antiphospholipid syndrome is usually diagnosed based on medical history and clinical and imaging findings.

Advanced research clinical developments in treating antiphospholipid syndrome help to accelerate market growth. For instance, in December 2022, Qilu Hospital of Shandong University conducted a clinical trial on the Efficacy and Safety of Telitacicept Followed by rituximab Therapy on Antiphospholipid Syndrome Secondary to Systemic lupus erythematosus (SLE). The intervention involves Telitacicept 160mg given once a week for 24 weeks.

Moreover, in March 2022, Hôpitaux de Paris conducted an interventional study on the Evaluation of the Benefit of Adjuvant Treatment with Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome.

This clinical trial is to evaluate the benefit of the addition or no of hydroxychloroquine to conventional treatment in obstetric antiphospholipid syndrome (APS). Thus, due to the above factors, the market is expected to boost over the forecast period.

Moreover, key players in the industry developing innovative research studies in antiphospholipid syndrome treatments would drive this market growth. For instance, in November 2023, a new study by Hospital for Special Surgery (HSS) investigators found that an initial high-risk antibody profile for antiphospholipid syndrome (APS) tended to remain high in pediatric patients. The results were presented in a poster session at the American College of Rheumatology (ACR) Convergence 2023, the ACR's annual meeting.

Also, in November 2022, the Geneva University Hospitals (HUG), the University of Geneva (UNIGE), and their spin-off Endotelix created the best possible target molecule for the antibodies responsible for antiphospholipid syndrome. This discovery will enable a new screening test to be developed. This auto-immune syndrome leads to the thromboses responsible for strokes and heart attacks.

Restraints

Factors such as the complications associated with antiphospholipid syndrome, high treatment costs, lack of awareness & misdiagnoses or underdiagnoses, limited treatment options, and challenges in diagnosis & conducting clinical trials are expected to hamper the market.

For more details on this report – Request for Sample

Segment Analysis

The global antiphospholipid syndrome market is segmented based on type, treatment, route of administration, distribution channels, and region.

The medications segment accounted for approximately 54.3% of the global antiphospholipid syndrome market share

The medications segment is expected to hold the largest market share over the forecast period. The rising clinical trials of treatment drugs globally have contributed to the growing demand for antiphospholipid syndrome treatment.

According to clinicalTrials.gov, in January 2023, the University of Turin, Italy conducted a clinical trial on Belimumab Therapy for Refractory and Non-criteria Manifestations of antiphospholipid syndrome.

The primary objective of the BeLimumab Antiphospholipid Syndrome Trial (BLAST) is to evaluate the safety and tolerability of belimumab for up to 24 months in patients with persistent positivity and clinical features attributable that are resistance to warfarin and heparin.

Moreover, in January 2023, the Institute of Hematology & Blood Diseases Hospital conducted a clinical trial on the Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome with Secondary Thrombocytopenia.

This study aims to provide a new treatment option for the clinical treatment of antiphospholipid syndrome with secondary thrombocytopenia to drive this segment's growth.

Geographical Analysis

North America accounted for approximately 43.3% of the global antiphospholipid syndrome market share

North America region is expected to hold the largest market share over the forecast period The rising incidence and prevalence of APS, particularly among the aging population, are driving market growth in this region.

According to the Medspace publication in November 2023, the incidence of APS is approximately 5 cases per 100,000 persons per year, and the prevalence is approximately 40-50 cases per 100,000 persons.

In addition, major key players' presence and new drug launches & approvals would drive this market growth. For instance, in June 2022, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism directly after they have been treated with a blood thinner given by injection for at least five days.

Also, in October 2023, Bio-Rad Laboratories introduced the BioPlex 2200 Antiphospholipid Syndrome (APL-S) IgM kit is a multiplex flow immunoassay intended for the semi-quantitative detection of IgM antibodies to Cardiolipin (CE) and lBeta-2 Glycoprotein I (j32GPI) in human serum and plasma.

The BioPlex 2200 System is a fully automated, random access multiplex system that allows clinical laboratories to maximize efficiency for autoimmune, infectious disease, and specialty testing.

Market Segmentation

By Type
• Primary Antiphospholipid Syndrome
• Secondary Antiphospholipid Syndrome
• Catastrophic Antiphospholipid Syndrome

By Treatment
• Medications
Warfarin
Enoxaparin
Rituximab
Hydroxychloroquine
• Prophylactic Therapy
• Others

By Route of Administration
• Oral
• Parenteral
• Others

By Distribution Channels
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the antiphospholipid syndrome market include Genentech Inc., F. Hoffmann-La Roche, Sanofi S.A, LGM Pharma, Taro Pharmaceuticals, Apotex PharmaChem, Teva Pharmaceuticals, Bristol Myers Squibb, Qilu Pharmaceuticals, Sigma Aldrich among others.

Key Developments

 In February 2024, Werfen announced it had received the CE mark for its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents under the European Union's (EU) In Vitro Diagnostic Medical Devices Regulation (IVDR).

Why Purchase the Report??
• To visualize the global antiphospholipid syndrome market segmentation based on type, treatment, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global antiphospholipid syndrome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global antiphospholipid syndrome market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies